Ad
related to: orphan drug
Search results
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 hours ago– Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 – – UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury ...
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
Zacks via Yahoo Finance· 1 day agoWinrevair is the first novel activin signaling inhibitor approved by the FDA to treat PAH. The FDA...
Belite Bio completes enrollment for STGD1 treatment trial By Investing.com
Investing.com· 6 days agoBelite Bio, Inc (NASDAQ: BLTE), a biopharmaceutical company, has recently completed the enrollment...
Tonix's TNX-2900 gains FDA rare pediatric disease tag By Investing.com
Investing.com· 3 days agoPWS is known as the most common genetic cause of life-threatening obesity in children. The FDA's...
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
Zacks via Yahoo Finance· 6 days agoThe FDA has granted orphan drug designation to LSTA1 for the treatment of pancreatic cancer and GBM....
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination...
WROC Rochester· 13 hours agoGenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in...
This small-cap stock is expected to take off - if its weight-loss pill trial succeeds
Morningstar· 5 hours agoThe stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company's pipeline, which includes an oral treatment for obesity that one bank believes ...
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
Zacks via Yahoo Finance· 3 days agoCorcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to...
ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib...
KTLA-TV Los Angeles· 4 days agoONO Pharmaceuticals, Co., Ltd. today announced it has completed target patient enrollment of the first arm (Part A) of the PROSPECT Study, a Phase 2 clinical trial evaluating the safety and ...
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with...
WROC Rochester· 13 hours agoTopline data is expected in the fourth quarter of 2024 and could support a supplemental New Drug...